|Bid||50.99 x 1800|
|Ask||51.25 x 3200|
|Day's Range||50.91 - 51.95|
|52 Week Range||36.15 - 64.94|
|Beta (5Y Monthly)||0.22|
|PE Ratio (TTM)||62.28|
|Forward Dividend & Yield||1.40 (2.67%)|
|Ex-Dividend Date||Aug 13, 2020|
|1y Target Est||59.73|
Operation Warp Speed is reupping with this partner to prove long-lasting prevention is better than treatment.
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.